Xevinapant in SCCHN is negative

[Palex80]

---

Members don't see this ad.

https://www.emdgroup.com/en/news/xevinapant-update.html

Too bad. I held high hopes for this one.

Another example, unfortunately, that phase II randomized data should be interpreted with a grain of salt.

You may recall the data from the randomized phase II trial reported in 2020.

 

[temujim]

It's a shame. Plausible mechanism of action in combo with RT. Will be interesting to see the trial data. Understand the company has pulled all support from active trials and I assume trials in development. Testing in other scenarios such as with SBRT probably not going to happen. Well, enjoyed the multiple wall street consulting calls while it lasted.

 

[communitydoc13]

https://www.emdgroup.com/en/news/xevinapant-update.html

Too bad. I held high hopes for this one.

Another example, unfortunately, that phase II randomized data should be interpreted with a grain of salt.

You may recall the data from the randomized phase II trial reported in 2020.
View attachment 388426

Randomness is weird, and a 100 pt trial is very susceptible to it.

One thing I’ve learned…when you see outcome curves diverge early in anything but stage IV disease (exception being when there is a plausible cause for such divergence like death by surgery in one arm) it’s probably a bogus effect.